CJC-1295 + Ipamorelin — Dual-Pathway GH Stimulation Protocol. Physician-Supervised
The CJC-1295 and ipamorelin combination is one of the most widely used GH peptide protocols in physician-supervised men’s health. By activating two different receptor pathways simultaneously — GHRH receptor and ghrelin receptor — research has investigated whether this dual stimulation produces GH release that exceeds what either compound achieves independently. It is available at OptiMale USA following baseline bloodwork and clinical assessment.
WHAT IS IT?
Understanding CJC-1295 / Ipamorelin
Growth hormone release from the pituitary is governed by two main signals: GHRH (growth hormone-releasing hormone), which primes the pituitary to release GH, and ghrelin, which triggers the actual GH pulse. CJC-1295 mimics GHRH — occupying and activating GHRH receptors to prime the pituitary. Ipamorelin mimics ghrelin — activating the GHSR (ghrelin receptor) to trigger GH secretion. Used together, they act on both arms of this system simultaneously.
Research has investigated this dual-pathway approach for producing amplified GH pulse amplitude and frequency compared to either compound alone. The combination is typically administered as a single subcutaneous injection before bed to align with the body’s natural GH release during deep sleep. At OptiMale USA, this combination is assessed individually — baseline IGF-1 testing is required, and dosing is adjusted based on your IGF-1 response throughout the protocol.
Quick Facts
Injection
Timeline: Sleep and recovery improvements in 1-3 weeks; body composition changes at 8-12 weeks
Lab required: Yes
Ongoing maintenance: Yes — cycling protocols and periodic lab monitoring
Pricing: Contact for Pricing
Related Treatments
Benefits
Two receptor pathways addressed simultaneously
GHRH receptor (CJC-1295) and ghrelin receptor (ipamorelin) are the two primary drivers of pituitary GH release. Research has investigated the combination for producing GH pulse amplitude and frequency beyond what single-pathway stimulation achieves.
Ipamorelin's selective hormonal profile
Ipamorelin does not significantly stimulate cortisol or prolactin — a selectivity that research has characterised as an advantage over older GHRP compounds. This means the combination targets GH release specifically without broad off-target hormonal effects.
Physiological pulsatile release
The combination uses CJC-1295 without DAC in most protocols, preserving the natural pulsatile pattern of GH secretion rather than producing constant elevation. Research has examined pulsatile GH release as more physiologically appropriate than sustained elevation.
Recovery, lean mass, and sleep research
GH and downstream IGF-1 are involved in protein synthesis, satellite cell activity, and tissue repair. Research has studied this combination's effects on GH and IGF-1 levels, sleep quality, and body composition markers in men with age-related GH decline.
Who Is This For?
Am I a Good Candidate?
Ideal For
- Men over 30 with documented low GH or IGF-1 levels through bloodwork
- Men experiencing age-related changes in recovery, sleep, body composition, or energy
- Men on TRT or other hormone programs who want to add physician-supervised GH support
- Men who want a well-researched combination approach rather than single-agent GH stimulation
Not Recommended If
- Men with active malignancy
- Men with pituitary disorders or significantly elevated baseline IGF-1
- Men under 25 or with open growth plates
- Men who have not had baseline IGF-1 testing prior to beginning a GH peptide protocol
Safety
Potential Side Effects
The combination is generally well tolerated. Side effects reflect those of both individual compounds and are typically mild. IGF-1 monitoring is essential throughout all GH peptide protocols at OptiMale USA.
- IGF-1 levels — assessed before starting and regularly throughout; dosing adjusted based on response
- Blood glucose — GH influences insulin sensitivity and is tracked at every follow-up
- Clinical response — sleep quality, energy, recovery, and body composition reviewed at check-ins
- Water retention — mild and usually transient
- Injection site reactions — mild, typically short-lived
- Mild headache or flushing — occasionally reported early in the protocol
Common Questions
Frequently Asked Questions
Why combine two compounds rather than using one?
CJC-1295 primes the pituitary through GHRH receptors. Ipamorelin triggers GH release through ghrelin receptors. These are two different biological steps in the GH secretion process. Research has investigated combining both — priming and triggering simultaneously — for producing GH pulse amplitude that exceeds what activating only one step achieves.
Are they given as one injection or two?
In most protocols the two compounds are mixed in a single injection, administered before bed. Your provider will guide you through preparation and injection technique. The mixing of these two compounds is standard practice in physician-supervised GH peptide protocols.
How long before I might notice changes?
GH peptide protocols work gradually through physiological restoration rather than rapid hormonal intervention. Most providers discuss changes in sleep depth and recovery quality appearing first — typically over weeks rather than days. Changes in body composition are typically observed over months. Your provider will set individualised expectations during your consultation based on your baseline bloodwork.
Get started
Discuss CJC-1295 + Ipamorelin With a Provider
Your free consultation is the first step. A licensed OptiMale USA provider will review your bloodwork, health history, and goals before making any recommendations.